119 related articles for article (PubMed ID: 16047355)
21. Preclinical evaluation of therapeutic effects of targeted cytotoxic analogs of somatostatin and bombesin on human gastric carcinomas.
Szepeshazi K; Schally AV; Nagy A; Wagner BW; Bajo AM; Halmos G
Cancer; 2003 Oct; 98(7):1401-10. PubMed ID: 14508826
[TBL] [Abstract][Full Text] [Related]
22. Role of ABC-cassette transporters (MDR1, MRP1, BCRP) in the development of primary and acquired multiple drug resistance in patients with early and metastatic breast cancer.
Kovalev AA; Tsvetaeva DA; Grudinskaja TV
Exp Oncol; 2013 Dec; 35(4):287-90. PubMed ID: 24382439
[TBL] [Abstract][Full Text] [Related]
23. A targeted cytotoxic somatostatin (SST) analogue, AN-238, inhibits the growth of H-69 small-cell lung carcinoma (SCLC) and H-157 non-SCLC in nude mice.
Kiaris H; Schally AV; Nagy A; Szepeshazi K; Hebert F; Halmos G
Eur J Cancer; 2001 Mar; 37(5):620-8. PubMed ID: 11290438
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238.
Plonowski A; Schally AV; Nagy A; Sun B; Szepeshazi K
Cancer Res; 1999 Apr; 59(8):1947-53. PubMed ID: 10213505
[TBL] [Abstract][Full Text] [Related]
25. Anticancer drug sensitivity and expression of multidrug resistance markers in early passage human sarcomas.
Hoffmann J; Schmidt-Peter P; Hänsch W; Naundorf H; Bunge A; Becker M; Fichtner I
Clin Cancer Res; 1999 Aug; 5(8):2198-204. PubMed ID: 10473106
[TBL] [Abstract][Full Text] [Related]
26. Effective therapy of experimental human malignant melanomas with a targeted cytotoxic somatostatin analogue without induction of multi-drug resistance proteins.
Keller G; Schally AV; Nagy A; Baker B; Halmos G; Engel JB
Int J Oncol; 2006 Jun; 28(6):1507-13. PubMed ID: 16685451
[TBL] [Abstract][Full Text] [Related]
27. Regression of U-87 MG human glioblastomas in nude mice after treatment with a cytotoxic somatostatin analog AN-238.
Kiaris H; Schally AV; Nagy A; Sun B; Szepeshazi K; Halmos G
Clin Cancer Res; 2000 Feb; 6(2):709-17. PubMed ID: 10690557
[TBL] [Abstract][Full Text] [Related]
28. Effective treatment of H838 human non-small cell lung carcinoma with a targeted cytotoxic somatostatin analog, AN-238.
Szereday Z; Schally AV; Szepeshazi K; Bajo AM; Hebert F; Halmos G; Nagy A
Int J Oncol; 2003 May; 22(5):1141-6. PubMed ID: 12684683
[TBL] [Abstract][Full Text] [Related]
29. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
[TBL] [Abstract][Full Text] [Related]
30. Expression of multidrug resistance 1 (MDR1), multidrug resistance-related protein 1 (MRP1), lung resistance protein (LRP), and breast cancer resistance protein (BCRP) genes and clinical outcome in childhood acute lymphoblastic leukemia.
Kourti M; Vavatsi N; Gombakis N; Sidi V; Tzimagiorgis G; Papageorgiou T; Koliouskas D; Athanassiadou F
Int J Hematol; 2007 Aug; 86(2):166-73. PubMed ID: 17875533
[TBL] [Abstract][Full Text] [Related]
31. Suppression of BCRP expression and restoration of sensitivity to chemotherapy in multidrug-resistant HCC cell line HEPG2/ADM by RNA interference.
Li H; Zhou S; Li T; Liu Z; Wu J; Zeng G; Liu C; Gong J
Hepatogastroenterology; 2012 Oct; 59(119):2238-42. PubMed ID: 23435138
[TBL] [Abstract][Full Text] [Related]
32. Regulations of ABCB1 and ABCG2 expression through MAPK pathways in acute lymphoblastic leukemia cell lines.
Tomiyasu H; Watanabe M; Sugita K; Goto-Koshino Y; Fujino Y; Ohno K; Sugano S; Tsujimoto H
Anticancer Res; 2013 Dec; 33(12):5317-23. PubMed ID: 24324065
[TBL] [Abstract][Full Text] [Related]
33. Internalization of cytotoxic analog AN-152 of luteinizing hormone-releasing hormone induces apoptosis in human endometrial and ovarian cancer cell lines independent of multidrug resistance-1 (MDR-1) system.
Günthert AR; Gründker C; Bongertz T; Schlott T; Nagy A; Schally AV; Emons G
Am J Obstet Gynecol; 2004 Oct; 191(4):1164-72. PubMed ID: 15507937
[TBL] [Abstract][Full Text] [Related]
34. Targeted cytotoxic somatostatin analogue AN-238 inhibits somatostatin receptor-positive experimental colon cancers independently of their p53 status.
Szepeshazi K; Schally AV; Halmos G; Armatis P; Hebert F; Sun B; Feil A; Kiaris H; Nagy A
Cancer Res; 2002 Feb; 62(3):781-8. PubMed ID: 11830533
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207.
Stangelberger A; Schally AV; Nagy A; Szepeshazi K; Kanashiro CA; Halmos G
Prostate; 2006 Feb; 66(2):200-10. PubMed ID: 16173040
[TBL] [Abstract][Full Text] [Related]
36. Breast cancer resistance protein expression is associated with early recurrence and decreased survival in resectable pancreatic cancer patients.
Lee SH; Kim H; Hwang JH; Lee HS; Cho JY; Yoon YS; Han HS
Pathol Int; 2012 Mar; 62(3):167-75. PubMed ID: 22360504
[TBL] [Abstract][Full Text] [Related]
37. Targeted cytotoxic somatostatin analog AN-162 inhibits growth of human colon carcinomas and increases sensitivity of doxorubicin resistant murine leukemia cells.
Hohla F; Buchholz S; Schally AV; Krishan A; Rick FG; Szalontay L; Papadia A; Halmos G; Koster F; Aigner E; Datz C; Seitz S
Cancer Lett; 2010 Aug; 294(1):35-42. PubMed ID: 20156671
[TBL] [Abstract][Full Text] [Related]
38. Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers.
Nagy A; Schally AV
Biol Reprod; 2005 Nov; 73(5):851-9. PubMed ID: 16033997
[TBL] [Abstract][Full Text] [Related]
39. Real-time quantitative polymerase chain reaction for BCRP, MDR1, and MRP1 mRNA levels in lymphocytes and monocytes.
Moon YJ; Zhang S; Morris ME
Acta Haematol; 2007; 118(3):169-75. PubMed ID: 17911978
[TBL] [Abstract][Full Text] [Related]
40. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
